Dutch startup OASYS NOW clinches €1M prize at Slush
The company is pioneering personalized healthcare and precision medicine, focusing on cardiology, rare diseases, and multiple chronic conditions.
Published on November 22, 2024
© Slush
OASYS NOW, a Delft-based startup, has won the prestigious Slush 100 competition, securing €1 million in funding. The company is pioneering personalized healthcare and precision medicine, focusing on cardiology, rare diseases, and multiple chronic conditions. Their AI-powered platform streamlines clinical trial patient identification and recruitment, addressing a critical industry challenge where 80% of trials fail to meet initial enrollment targets.
OASYS NOW's innovative approach accelerates patient cohort identification and empowers individuals to manage their health data and discover relevant clinical trials. This victory at Slush will fuel the company's expansion and computing power, potentially transforming the landscape of clinical research and patient care.
Innovative solutions for patient empowerment
Central to OASYS NOW's mission is the empowerment of individuals in managing their health data. Their GRIP app and ELaiGIBLE platform are designed to give users control over their health records, facilitating the discovery of clinical trials that align with their specific conditions. This user-centric approach not only enhances patient autonomy but also accelerates the identification of suitable patient cohorts from months to mere minutes. By bridging the gap between patients and researchers, OASYS NOW is poised to make personalized medicine more accessible and effective.
Personalized medicine offers hope for ultra-rare diseases care
A study has unveiled the first roadmap for developing genetic therapies for ultra-rare diseases affecting only one person worldwide.
Expanding horizons in healthcare
Initially focused on cardiology and rare diseases, OASYS NOW is now broadening its scope to include brain-related diseases like Alzheimer's and Parkinson's, as well as immunology. CTO Sara Okhuijsen emphasizes the adaptability of their technology across various therapeutic areas. This expansion is driven by a keen awareness of where the greatest needs lie and which clients can quickly integrate their solutions. By keeping pace with emerging healthcare challenges, OASYS NOW aims to remain at the forefront of medical innovation.
A commitment to privacy and data security
In an era where data privacy is paramount, OASYS NOW stands out with its commitment to secure and ethical data handling. Their platform ensures that health data remains encrypted and anonymized, adhering to General Data Protection Regulation (GDPR) standards and continuously monitored for compliance. Co-founder Nima Salami underscores the importance of transparency and user control, allowing individuals to decide how their data is used. This privacy-centric approach not only fosters trust among users but also opens new avenues for collaborative research through federated learning.